Loading…
Reported covered position: Legislative Director - Rep. Brooks, 2018 - 2019; Legislative Director - Rep. Valadao, 2015-2018; Legislative Assistant - Rep. Valadao, 2014-2015.
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PANO AI via FORBES-TATE
2026 · third_quarter · Q3
Issues related to wildfire related appropriations bills.
Issues related to wildfire related appropriations bills.
Issues related to wildfire related appropriations bills.
Source: Senate LDA
| GLOBAL MEDICAL RESPONSE |
| 20 |
| 2022–2026 |
| SPACE EXPLORATION TECHNOLOGIES CORP. | 20 | 2019–2023 |
| VIR BIOTECHNOLOGY, INC. | 20 | 2020–2024 |
| COALITION FOR ENERGY ASSISTANCE MODERNIZATION | 19 | 2021–2025 |
| EMERGENT BIOSOLUTIONS | 19 | 2019–2023 |
| NATIONAL GRID USA SERVICE COMPANY, INC. D/B/A NATIONAL GRID | 19 | 2022–2026 |
| COALITION FOR CANNABIS POLICY, EDUCATION, AND REGULATION | 18 | 2021–2024 |
| GENERAL ATOMICS | 18 | 2022–2026 |
| REGENESIS | 17 | 2020–2024 |
| ASSOCIATION OF AMERICAN RAILROADS | 16 | 2019–2023 |
| GENOVAC, LLC | 14 | 2020–2023 |
| GILEAD SCIENCES, INC. | 14 | 2023–2026 |
| INDEPENDENT PHARMACY COOPERATIVE | 14 | 2020–2026 |
| LYKOS THERAPEUTICS | 14 | 2023–2025 |
| VERDE TECHNOLOGIES | 13 | 2019–2022 |
| ASSOCIATION OF AMERICAN MEDICAL COLLEGES | 12 | 2024–2026 |
| COALITION FOR APP FAIRNESS | 12 | 2021–2024 |
| LUNDBECK LLC | 12 | 2019–2021 |
| NATIONAL PEST MANAGEMENT ASSOCIATION | 12 | 2022–2024 |
| CLARITEV (FKA MULTIPLAN CORPORATION) | 11 | 2024–2026 |
| SAREPTA THERAPEUTICS | 11 | 2019–2022 |
| THE PARTNERSHIP FOR AMERICAS HEALTH CARE FUTURE | 11 | 2019–2021 |
| ALTRIA CLIENT SERVICES LLC | 10 | 2019–2021 |
| AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION | 10 | 2024–2026 |
| BAYER CORPORATION | 10 | 2019–2021 |
| CEO CLIMATE DIALOGUE | 10 | 2021–2023 |
| INTERSTATE NATURAL GAS ASSOCIATION OF AMERICA | 10 | 2019–2021 |
| NATIONAL HOCKEY LEAGUE | 10 | 2019–2021 |
| NCCS | 10 | 2023–2024 |
| Sorrento Therapeutics, Inc. | 10 | 2019–2021 |
| TARGET CORPORATION | 10 | 2020–2022 |
| UNIVERSITY OF SOUTHERN CALIFORNIA | 10 | 2019–2021 |
| VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIES | 10 | 2019–2021 |
| BIPARTISAN POLICY CENTER ACTION | 9 | 2022–2023 |
| CAPITOL SOLUTIONS ON BEHALF OF BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. | 9 | 2020–2022 |
| CSL BEHRING | 9 | 2023–2025 |
| CTIA - THE WIRELESSS ASSOCIATION | 9 | 2019–2021 |
| GENENTECH | 9 | 2024–2026 |
| HALOZYME THERAPEUTICS, INC. | 9 | 2019–2021 |
| HERMEUS CORPORATION | 9 | 2021–2023 |
| PUBLIC SERVICE COMPANY OF NEW MEXICO | 9 | 2022–2024 |
| REVANGENIX | 9 | 2024–2025 |
| SONY INTERACTIVE ENTERTAINMENT LLC | 9 | 2023–2026 |
| STORER TEST EXPRESS DBA BUSTEST EXPRESS | 9 | 2021–2023 |
| T-MOBILE | 9 | 2019–2021 |
| HEALTHY.IO (US), INC. | 8 | 2023–2025 |
| LIVE NATION ENTERTAINMENT, INC. | 8 | 2019–2021 |
| NATIONAL ASSOCIATION OF PROTON THERAPY | 8 | 2019–2021 |
| RECREATIONAL OFF-HIGHWAY VEHICLE ASSOCIATION | 8 | 2023–2024 |
| SOLAREDGE TECHNOLOGIES INC. | 8 | 2024–2026 |
| ALEXION PHARMACEUTICALS, INC. | 7 | 2020–2021 |
| CONTESSA HEALTH, INC. | 7 | 2020–2021 |
| HOMEWARD HEALTH | 7 | 2023–2024 |
| MERCK KGAA DARMSTADT GERMANY | 7 | 2024 |
| SIDLEY AUSTIN LLP ON BEHALF OF PACIFIC AUTO RECYCLING CENTER | 7 | 2024–2025 |
| SIDLEY AUSTIN LLP ON BEHALF OF UNIVERSAL SERVICES RECYCLING | 7 | 2024–2025 |
| VENATORX PHARMACEUTICALS | 7 | 2021–2022 |
| AGLOGIC | 6 | 2025–2026 |
| MERCK ANIMAL HEALTH | 6 | 2023–2024 |
| MOLINA HEALTHCARE, INC. | 6 | 2020–2021 |
| SAFE AND ETHICAL PPE ACCESS ALLIANCE | 6 | 2024–2025 |
| WHITEPAGES, INC. | 6 | 2023–2024 |
| ABBOTT LABORATORIES | 5 | 2019–2020 |
| ARCTURUS THERAPEUTICS | 5 | 2020–2021 |
| DATAVANT | 5 | 2024 |
| DENTSPLY SIRONA | 5 | 2025 |
| NEW VENTURE FUND ON BEHALF OF CENTER FOR SECURE AND MODERN ELECTIONS | 5 | 2022–2023 |
| SEVEN STATES POWER CORPORATION | 5 | 2024–2025 |
| SUMRELL SUGG OBO CAROLINAEAST HEALTH SYSTEM | 5 | 2025–2026 |
| THE CURE COALITION | 5 | 2025–2026 |
| VISION MANAGEMENT SERVICES GTI | 5 | 2025–2026 |
| A PLACE FOR MOM, INC. | 4 | 2019–2020 |
| BELLEROPHON THERAPEUTICS | 4 | 2020 |
| JSI | 4 | 2025 |
| JUPITER POWER LLC | 4 | 2026 |
| NATIONAL ASSOCIATION OF LANDSCAPE PROFESSIONALS | 4 | 2019–2020 |
| ORBITAL EFFECTS | 4 | 2020–2021 |
| STATE OF NORTH CAROLINA | 4 | 2026 |
| THE WILLIAMS COMPANIES, INC. | 4 | 2020–2021 |
| TYSON SHARED SERVICES, INC. | 4 | 2025–2026 |
| ULTRAGENYX PHARMACEUTICAL | 4 | 2023 |
| WESTERN DIGITAL | 4 | 2025–2026 |
| CONDUENT BUSINESS SERVICES, LLC | 3 | 2023–2024 |
| GL HOMES | 3 | 2021–2022 |
| HUMAN RIGHTS CAMPAIGN | 3 | 2023 |
| U.S. BEET SUGAR ASSOCIATION (USBSA) | 3 | 2021 |
| UNICEF USA | 3 | 2025 |
| ACTIVEHOURS INC., D/B/A EARNIN | 2 | 2021 |
| DS ADMIRAL BIDCO, LLC | 2 | 2023 |
| I AM ALS | 2 | 2026 |
| PANO AI | 2 | 2026 |
| BARILLA AMERICA INC. | 1 | 2025 |
| INTERNATIONAL WOOD PRODUCTS ASSOCIATION | 1 | 2025 |
| SPERO THERAPEUTICS, INC. | 1 | 2021 |
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
Ensuring Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Ensuring Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Ensuring Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Energy and Water Development and Related Agencies Appropriations Act, 2026
Client: GENERAL ATOMICS · Firm: FORBES-TATE
Issues related to civil works projects, energy programs, and environmental activities; Issues related to H.R. 4553/S. 3293 - Energy and Water Development and Related Agencies Appropriations Act, 2026.
Energy and Water Development and Related Agencies Appropriations Act, 2026
Client: GENERAL ATOMICS · Firm: FORBES-TATE
Issues related to civil works projects, energy programs, and environmental activities; Issues related to H.R. 4553/S. 3293 - Energy and Water Development and Related Agencies Appropriations Act, 2026.
Home Appliance Protection and Affordability Act
Client: A.O. SMITH CORPORATION · Firm: FORBES-TATE
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to appliance standards & EPCA reform in H.R. 4626 - Dont Mess With My Home Appliances Act.
Home Appliance Protection and Affordability Act
Client: A.O. SMITH CORPORATION · Firm: FORBES-TATE
Issues related to energy efficiency and drinking water policy; Issues related to per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to the definition of water heater under energy conservation standards; Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to appliance standards & EPCA reform in H.R. 4626 - Home Appliance Protection and Affordability Act.
Home Appliance Protection and Affordability Act
Client: A.O. SMITH CORPORATION · Firm: FORBES-TATE
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to appliance standards & EPCA reform in H.R. 4626 - Home Appliance Protection and Affordability Act.
Home Appliance Protection and Affordability Act
Client: A.O. SMITH CORPORATION · Firm: FORBES-TATE
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to appliance standards & EPCA reform in H.R. 4626 - Home Appliance Protection and Affordability Act.
Home Appliance Protection and Affordability Act
Client: A.O. SMITH CORPORATION · Firm: FORBES-TATE
Issues related to energy efficiency and drinking water policy; Issues related to per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to the definition of water heater under energy conservation standards; Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to appliance standards & EPCA reform in H.R. 4626 - Don't Mess With My Home Appliances Act.
Home Appliance Protection and Affordability Act
Client: A.O. SMITH CORPORATION · Firm: FORBES-TATE
Issues related to energy efficiency and drinking water policy; Issues related to per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to the definition of water heater under energy conservation standards; Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to appliance standards & EPCA reform in H.R. 4626 - Home Appliance Protection and Affordability Act.
Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to PL 119-6 - Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Energy relating to "Energy Conservation Program: Energy Conservation Standards for Consumer Gas-fired Instantaneous Water Heaters"; Issues related to H.R. 4721/S. 2436 - Healthy H2O Act.
Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to PL 119-6 - Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Energy relating to "Energy Conservation Program: Energy Conservation Standards for Consumer Gas-fired Instantaneous Water Heaters"; Issues related to H.R. 4721/S. 2436 - Healthy H2O Act.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Drug Shortage Compounding Patient Access Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44); Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Doctor Knows Best Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Doctor Knows Best Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44); Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Doctor Knows Best Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44); Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44); Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Medicare Patient Access and Practice Stabilization Act of 2025
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Radiology Outpatient Ordering Transmission (ROOT) Act
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Radiology Outpatient Ordering Transmission (ROOT) Act
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44); Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Radiology Outpatient Ordering Transmission (ROOT) Act
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Treat and Reduce Obesity Act of 2025
Client: ELI LILLY AND COMPANY FKA LILLY USA, LLC · Firm: FORBES-TATE
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Equitable Community Access to Pharmacist Services Act
Client: INDEPENDENT PHARMACY COOPERATIVE · Firm: FORBES-TATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to PL 119-6 - Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Energy relating to "Energy Conservation Program: Energy Conservation Standards for Consumer Gas-fired Instantaneous Water Heaters"; Issues related to H.R. 4721/S. 2436 - Healthy H2O Act.
Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to PL 119-6 - Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Energy relating to "Energy Conservation Program: Energy Conservation Standards for Consumer Gas-fired Instantaneous Water Heaters"; Issues related to H.R. 4721/S. 2436 - Healthy H2O Act.
Energy and Water Development and Related Agencies Appropriations Act, 2026
Client: GENERAL ATOMICS · Firm: FORBES-TATE
Issues related to civil works projects, energy programs, and environmental activities; Issues related to H.R. 4553/S. 3293 - Energy and Water Development and Related Agencies Appropriations Act, 2026.
Energy and Water Development and Related Agencies Appropriations Act, 2026
Client: GENERAL ATOMICS · Firm: FORBES-TATE
Issues related to civil works projects, energy programs, and environmental activities; Issues related to H.R. 4553/S. 3293 - Energy and Water Development and Related Agencies Appropriations Act, 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to S.3822 - Break Up Big Medicine Act.
Issues related to S.3822 - Break Up Big Medicine Act.
Issues related to S.3822 - Break Up Big Medicine Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Bipartisan Health Care Act
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Bipartisan Health Care Act
Client: AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION · Firm: FORBES-TATE
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Issues related to wildfire related appropriations bills.
Issues related to wildfire related appropriations bills.
Issues related to wildfire related appropriations bills.
Issues related to wildfire related appropriations bills.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WESTERN DIGITAL via FORBES-TATE
2026 · third_quarter · Q3
Issues related to data storage.
Issues related to data storage.
Issues related to data storage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
VISION MANAGEMENT SERVICES GTI via FORBES-TATE
2026 · third_quarter · Q3
Issues related to hemp & cannabis policy.
Issues related to hemp & cannabis policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
UNIVERSAL MUSIC GROUP RECORDINGS, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to copyright and licensing; Issues related to artificial intelligence; Issues related to creator rights.
Issues related to copyright and licensing; Issues related to artificial intelligence.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
I AM ALS via FORBES-TATE
2026 · third_quarter · Q3
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TYSON SHARED SERVICES, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing.
THE CURE COALITION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to medical innovation and drug development.
Issues related to medical innovation and drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
STATE OF NORTH CAROLINA via FORBES-TATE
2026 · third_quarter · Q3
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
SUMRELL SUGG OBO CAROLINAEAST HEALTH SYSTEM via FORBES-TATE
2026 · third_quarter · Q3
Issues related to hospital reimbursement.
Issues related to hospital reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SONY INTERACTIVE ENTERTAINMENT LLC via FORBES-TATE
2026 · third_quarter · Q3
Issues related to antitrust, competition, and the gaming industry.
Issues related to gaming-related tariff policies.
Issues related to operational improvements for legislation related to issues involving online safety and accountability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS, INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037/S. 1500 - Access to Breast Cancer Diagnosis Act of 2025.
SOLAREDGE TECHNOLOGIES INC. via FORBES-TATE
2026 · third_quarter · Q3
Issues related to the implementation of the 45X tax credit; Issues related to cybersecurity and enhanced energy infrastructure.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
ELI LILLY AND COMPANY FKA LILLY USA, LLC via FORBES-TATE
2026 · third_quarter · Q3
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (PL 119-21).
GENENTECH via FORBES-TATE
2026 · third_quarter · Q3
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
EXELON CORPORATION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to book minimum tax in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21)
Issues related to affordability, transmission policy and workforce development; Issues related to clean energy tax credits; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to transmission.
Issues related to affordability, transmission policy and workforce development; Issues related to transmission.
ASSOCIATION OF AMERICAN MEDICAL COLLEGES via FORBES-TATE
2026 · third_quarter · Q3
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education; Issues related to financial assistance for medical education.
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education.
Issues related to teaching hospitals; Issues related to hospital reimbursement.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues related to surprise billing; Issues related to prior authorization in Medicare and Medicaid.
PACIFIC GAS AND ELECTRIC via FORBES-TATE
2026 · third_quarter · Q3
Energy issues related to spent nuclear fuel policy, cybersecurity, and physical security; Issues related to FERC.
Issues related to tax pensions; Issues related to implementation of the One Big Beautiful Bill Act (PL 119-21).
Interior Appropriations related to energy resiliency in tribal communities.
A.O. SMITH CORPORATION via FORBES-TATE
2026 · third_quarter · Q3
Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to PL 119-6 - Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Energy relating to "Energy Conservation Program: Energy Conservation Standards for Consumer Gas-fired Instantaneous Water Heaters"; Issues related to H.R. 4721/S. 2436 - Healthy H2O Act.
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to appliance standards & EPCA reform in H.R. 4626 - Home Appliance Protection and Affordability Act.
JUPITER POWER LLC via FORBES-TATE
2026 · third_quarter · Q3
Issues related to tariff policies.
Issues related to deploying large scale battery technologies.
Issues related to the One Big Beautiful Bill Act (P.L. 119-21).
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2026 · third_quarter · Q3
Issues related to S.3822 - Break Up Big Medicine Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation Program in the One Big Beautiful Bill Act (PL 119-21).
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2026 · third_quarter · Q3
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
GENERAL ATOMICS via FORBES-TATE
2026 · third_quarter · Q3
Issues related to civil works projects, energy programs, and environmental activities; Issues related to H.R. 4553/S. 3293 - Energy and Water Development and Related Agencies Appropriations Act, 2026.
Issues related to civil works projects, energy programs, and environmental activities; Issues related to advanced nuclear energy.
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
PANO AI via FORBES-TATE
2026 · third_quarter · RR
Issues related to wildfire related appropriations bills.
Issues related to wildfire related appropriations bills.
Issues related to wildfire related appropriations bills.
NATIONAL GRID USA SERVICE COMPANY, INC. D/B/A NATIONAL GRID via FORBES-TATE
2026 · third_quarter · 3T
Issues related to permitting, affordability, and reliability.
Issues related to permitting, affordability, and reliability.
Issues related to permitting, affordability, and reliability.
SOLAREDGE TECHNOLOGIES INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the implementation of the 45X tax credit; Issues related to cybersecurity and enhanced energy infrastructure.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
ASSOCIATION OF AMERICAN MEDICAL COLLEGES via FORBES-TATE
2026 · second_quarter · Q2
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education; Issues related to financial assistance for medical education.
Issues related to teaching hospitals; Issues related to hospital reimbursement.
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TYSON SHARED SERVICES, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to Xylazine usage.
AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Issues related to surprise billing; Issues related to prior authorization in Medicare and Medicaid.
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
THE CURE COALITION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to medical innovation and drug development.
Issues related to medical innovation and drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation Program in the One Big Beautiful Bill Act (P.L. 119-21).
Issues related to S.3822 - Break Up Big Medicine Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
PACIFIC GAS AND ELECTRIC via FORBES-TATE
2026 · second_quarter · Q2
Issues related to tax pensions; Issues related to implementation of the One Big Beautiful Bill Act (PL 119-21).
Interior Appropriations related to energy resiliency in tribal communities.
Energy issues related to spent nuclear fuel policy, cybersecurity, and physical security; Issues related to FERC.
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
STATE OF NORTH CAROLINA via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
VISION MANAGEMENT SERVICES GTI via FORBES-TATE
2026 · second_quarter · Q2
Issues related to hemp & cannabis policy.
Issues related to hemp & cannabis policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUMRELL SUGG OBO CAROLINAEAST HEALTH SYSTEM via FORBES-TATE
2026 · second_quarter · Q2
Issues related to hospital reimbursement.
Issues related to hospital reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
SONY INTERACTIVE ENTERTAINMENT LLC via FORBES-TATE
2026 · second_quarter · Q2
Issues related to gaming-related tariff policies.
Issues related to antitrust, competition, and the gaming industry.
Issues related to operational improvements for legislation related to issues involving online safety and accountability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WESTERN DIGITAL via FORBES-TATE
2026 · second_quarter · Q2
Issues related to data storage.
Issues related to data storage.
Issues related to data storage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL ATOMICS via FORBES-TATE
2026 · second_quarter · Q2
Issues related to civil works projects, energy programs, and environmental activities; Issues related to H.R. 4553/S. 3293 - Energy and Water Development and Related Agencies Appropriations Act, 2026.
Issues related to civil works projects, energy programs, and environmental activities; Issues related to advanced nuclear energy.
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
AGLOGIC via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the importance of science-based decisions with respect to crop protection tools in U.S. agriculture.
Issues related to the importance of science-based decisions with respect to crop protection tools in U.S. agriculture.
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
NATIONAL GRID USA SERVICE COMPANY, INC. D/B/A NATIONAL GRID via FORBES-TATE
2026 · second_quarter · Q2
Issues related to permitting, affordability, and reliability.
Issues related to permitting, affordability, and reliability.
Issues related to permitting, affordability, and reliability.
A.O. SMITH CORPORATION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs and other China issues.
Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to PL 119-6 - Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Energy relating to "Energy Conservation Program: Energy Conservation Standards for Consumer Gas-fired Instantaneous Water Heaters"; Issues related to H.R. 4721/S. 2436 - Healthy H2O Act.
JUPITER POWER LLC via FORBES-TATE
2026 · second_quarter · Q2
Issues related to the One Big Beautiful Bill Act (P.L. 119-21).
Issues related to tariff policies.
Issues related to tariff policies.
NOVARTIS, INC. via FORBES-TATE
2026 · second_quarter · Q2
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnosis Act of 2025.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
ELI LILLY AND COMPANY FKA LILLY USA, LLC via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
GENENTECH via FORBES-TATE
2026 · second_quarter · Q2
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to the 340B Drug Pricing Program.
Intellectual property and process patent related issues.
EXELON CORPORATION via FORBES-TATE
2026 · second_quarter · Q2
Issues related to affordability, transmission policy and workforce development; Issues related to clean energy tax credits; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to transmission.
Issues related to book minimum tax in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (P.L. 119-21)
Issues related to affordability, transmission policy and workforce development; Issues related to transmission.
I AM ALS via FORBES-TATE
2026 · third_quarter · RR
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
CLARITEV (FKA MULTIPLAN CORPORATION) via FORBES-TATE
2026 · second_quarter · 2T
Issues related to anti-trust.
Issues related to payment for healthcare services; Issues related to healthcare data transparency.
Issues pertaining to payment for healthcare services and healthcare data transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2026 · first_quarter · Q1
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
VISION MANAGEMENT SERVICES GTI via FORBES-TATE
2026 · first_quarter · Q1
Issues related to hemp & cannabis policy.
Issues related to hemp & cannabis policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TYSON SHARED SERVICES, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to Xylazine usage.
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing.
THE CURE COALITION via FORBES-TATE
2026 · first_quarter · Q1
Issues related to medical innovation and drug development.
Issues related to medical innovation and drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2026 · first_quarter · Q1
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SUMRELL SUGG OBO CAROLINAEAST HEALTH SYSTEM via FORBES-TATE
2026 · first_quarter · Q1
Issues related to hospital reimbursement.
Issues related to hospital reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SONY INTERACTIVE ENTERTAINMENT LLC via FORBES-TATE
2026 · first_quarter · Q1
Issues related to gaming-related tariff policies.
Issues related to antitrust, competition, and the gaming industry.
Issues related to operational improvements for legislation related to issues involving online safety and accountability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SOLAREDGE TECHNOLOGIES INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to the implementation of the 45X tax credit; Issues related to cybersecurity and enhanced energy infrastructure.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
PACIFIC GAS AND ELECTRIC via FORBES-TATE
2026 · first_quarter · Q1
Energy issues related to spent nuclear fuel policy, cybersecurity, and physical security.
Issues related to tax pensions; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Interior Appropriations related to energy resiliency in tribal communities.
NATIONAL GRID USA SERVICE COMPANY, INC. D/B/A NATIONAL GRID via FORBES-TATE
2026 · first_quarter · Q1
Issues related to permitting, affordability, and reliability.
Issues related to permitting, affordability, and reliability.
Issues related to permitting, affordability, and reliability.
WESTERN DIGITAL via FORBES-TATE
2026 · first_quarter · Q1
Issues related to data storage.
Issues related to data storage.
Issues related to data storage.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
STATE OF NORTH CAROLINA via FORBES-TATE
2026 · first_quarter · Q1
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
JUPITER POWER LLC via FORBES-TATE
2026 · first_quarter · Q1
Issues related to deploying large scale battery technologies.
Issues related to tariff policies.
Issues related to the One Big Beautiful Bill Act (P.L. 119-21).
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2026 · first_quarter · Q1
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
GENERAL ATOMICS via FORBES-TATE
2026 · first_quarter · Q1
Issues related to civil works projects, energy programs, and environmental activities; Issues related to advanced nuclear energy.
Issues related to civil works projects, energy programs, and environmental activities; Issues related to FY 2026 Energy and Water Appropriations Bill.
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS, INC. via FORBES-TATE
2026 · first_quarter · Q1
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
GENENTECH via FORBES-TATE
2026 · first_quarter · Q1
Issues related to the 340B Drug Pricing Program.
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
EXELON CORPORATION via FORBES-TATE
2026 · first_quarter · Q1
Issues related to book minimum tax in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to clean energy tax credits; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to affordability, transmission policy and workforce development; Issues related to clean energy tax credits; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to permitting; Issues related to transmission.
Issues related to affordability, transmission policy and workforce development; Issues related to clean energy tax credits; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to transmission.
ELI LILLY AND COMPANY FKA LILLY USA, LLC via FORBES-TATE
2026 · first_quarter · Q1
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
CLARITEV (FKA MULTIPLAN CORPORATION) via FORBES-TATE
2026 · first_quarter · Q1
Issues related to anti-trust.
Issues pertaining to payment for healthcare services and healthcare data transparency.
Issues related to payment for healthcare services; Issues related to healthcare data transparency.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION via FORBES-TATE
2026 · first_quarter · Q1
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Issues related to surprise billing; Issues related to prior authorization in Medicare and Medicaid.
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44); Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
AGLOGIC via FORBES-TATE
2026 · first_quarter · Q1
Issues related to the importance of science-based decisions with respect to crop protection tools in U.S. agriculture.
Issues related to the importance of science-based decisions with respect to crop protection tools in U.S. agriculture.
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
A.O. SMITH CORPORATION via FORBES-TATE
2026 · first_quarter · Q1
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation.
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to PL 119-6 - Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Energy relating to "Energy Conservation Program: Energy Conservation Standards for Consumer Gas-fired Instantaneous Water Heaters".
ASSOCIATION OF AMERICAN MEDICAL COLLEGES via FORBES-TATE
2026 · first_quarter · Q1
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education.
Issues related to teaching hospitals; Issues related to hospital reimbursement.
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education; Issues related to financial assistance for medical education.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
JUPITER POWER LLC via FORBES-TATE
2026 · first_quarter · RR
Issues related to deploying large scale battery technologies.
Issues related to deploying large scale battery technologies.
STATE OF NORTH CAROLINA via FORBES-TATE
2026 · first_quarter · RR
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
WESTERN DIGITAL via FORBES-TATE
2025 · first_quarter · RR
Issues related to data storage.
Issues related to data storage.
Issues related to data storage.
JSI via FORBES-TATE
2025 · fourth_quarter · 4@
Issues related to State Department humanitarian aid, recessions package.
Issues related to State Department humanitarian aid, recessions package.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEPENDENT PHARMACY COOPERATIVE via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2477 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2477 - Equitable Community Access to Pharmacist Services Act.
GLOBAL MEDICAL RESPONSE via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260).
Issues related to Medicare and Medicaid reimbursement, workforce issues and implementation of the Consolidated Appropriations Act of 2021 (PL 116-260); Issues related to Medicaid plan amendments.
Issues related to FEMA emergency transport response.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
GILEAD SCIENCES, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to healthcare, including improving patient access to advanced immunology therapies; Issues related to policies affecting biopharma products pricing, coverage and access in Medicare and Medicaid; Issues related to funding for HIV and HCV screening, linkage to care and treatment; Issues related to breast cancer screening.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
GENERAL ATOMICS via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to civil works projects, energy programs, and environmental activities.
Issues related to civil works projects, energy programs, and environmental activities.
Filing targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
Issues related to biopharmaceutical research and innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PACIFIC GAS AND ELECTRIC via FORBES-TATE
2025 · fourth_quarter · Q4
Energy issues related to spent nuclear fuel policy, cybersecurity, and physical security; Issues related to permitting; Issues related to BLM.
Interior Appropriations related to energy resiliency in tribal communities.
Energy issues related to spent nuclear fuel policy, cybersecurity, and physical security.
CLARITEV (FKA MULTIPLAN CORPORATION) via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to payment for healthcare services; Issues related to healthcare data transparency.
Issues pertaining to payment for healthcare services and healthcare data transparency.
Issues related to anti-trust.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL GRID USA SERVICE COMPANY, INC. D/B/A NATIONAL GRID via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to permitting, affordability, and reliability.
Issues related to permitting, affordability, and reliability.
Issues related to permitting, affordability, and reliability.
BARILLA AMERICA INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to food, agriculture and trade, and the Department of Commerce.
Issues related to food, agriculture and trade, and the Department of Commerce.
Issues related to food, agriculture and trade, and the Department of Commerce.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION OF AMERICAN MEDICAL COLLEGES via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education; Issues related to financial assistance for medical education.
Issues related to medical education and research; Issues related to funding for NIH and biomedical research; Issues related to diversity in medical education.
Issues related to teaching hospitals; Issues related to hospital reimbursement.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
VISION MANAGEMENT SERVICES GTI via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to hemp & cannabis policy.
Issues related to hemp & cannabis policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE CURE COALITION via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to medical innovation and drug development.
Issues related to medical innovation and drug development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SUMRELL SUGG OBO CAROLINAEAST HEALTH SYSTEM via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to hospital reimbursement.
Issues related to hospital reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
ELI LILLY AND COMPANY FKA LILLY USA, LLC via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025.
Issues regarding the Centers for Medicare and Medicaid Services National Coverage Decision (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease; Issues related to H.R. 4231/S. 1973 - Treat and Reduce Obesity Act of 2025; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025.
AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging; Issues related to Appropriate Use Criteria (AUC); Issues related to prior authorization in Medicare and Medicaid; Issues related to H.R. 639 - Doctor Knows Best Act of 2025; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to H.R. 5737/S. 1692 - Radiology Outpatient Ordering Transmission (ROOT) Act.
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to S. 891 - Bipartisan Health Care Act.
AGLOGIC via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to the importance of science-based decisions with respect to crop protection tools in U.S. agriculture.
Issues related to the importance of science-based decisions with respect to crop protection tools in U.S. agriculture.
Filing targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
A.O. SMITH CORPORATION via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation.
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to appliance standards & EPCA reform in H.R. 4626 - Dont Mess With My Home Appliances Act.
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21).
TYSON SHARED SERVICES, INC. via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing; Issues related to labor union work condition negotiation.
TENNESSEE RURAL HEALTH IMPROVEMENT ASSOCIATION via FORBES-TATE
2025 · fourth_quarter · Q4
Issues related to regulations that would restrict operations of farm bureau health insurance plans.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to workplace standards; Issues related to livestock and food pricing; Issues related to labor union work condition negotiation.
Issues related to Xylazine usage.
Issues related to workplace standards; Issues related to livestock and food pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to intellectual property and process patent.
Issues related to Medicare and Medicaid coverage and reimbursement; Issues related to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.
Issues related to the 340B Drug Pricing Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to affordability, transmission policy and workforce development; Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to permitting; Issues related to transmission.
Issues related to affordability, transmission policy and workforce development; Issues related to transmission.
Filing targets: HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE
Issues related to the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to H.R. 879/S. 1640 - Medicare Patient Access and Practice Stabilization Act of 2025; Issues related to Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to SUPPORT for Patients and Communities Reauthorization Act of 2025 (PL 119-44).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Energy issues related to spent nuclear fuel policy, cybersecurity, and physical security; Issues related to permitting; Issues related to BLM; Issues related to FERC.
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE, White House Office
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation.
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Issues related to energy efficiency and drinking water policy; Issues related to per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to the definition of water heater under energy conservation standards; Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to appliance standards & EPCA reform in H.R. 4626 - Home Appliance Protection and Affordability Act.
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs and other China issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Issues related to tariff policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to H.R. 3164/S. 2426 - Equitable Community Access to Pharmacist Services Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to wildfire related appropriations bills.
Issues related to wildfire related appropriations bills.
Issues related to wildfire related appropriations bills.
Issues related to wildfire related appropriations bills.
Issues related to permitting, affordability, and reliability.
Issues related to permitting, affordability, and reliability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing; Issues related to labor union work condition negotiation.
Issues related to workplace standards; Issues related to livestock and food pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Energy issues related to spent nuclear fuel policy, cybersecurity, and physical security; Issues related to permitting; Issues related to BLM; Issues related to FERC.
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE, White House Office
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to permitting, affordability, and reliability.
Issues related to permitting, affordability, and reliability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to appliance standards & EPCA reform in H.R. 4626 - Home Appliance Protection and Affordability Act.
Issues related to energy efficiency and drinking water policy; Issues related to per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to the definition of water heater under energy conservation standards; Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to appliance standards & EPCA reform in H.R. 4626 - Home Appliance Protection and Affordability Act.
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation.
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Issues related to deploying large scale battery technologies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to the 340b program; Issues related to S. 832 - EPIC Act of 2025.
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to affordability, transmission policy and workforce development; Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (P.L. 119-21); Issues related to permitting; Issues related to transmission.
Issues related to affordability, transmission policy and workforce development; Issues related to transmission.
Filing targets: HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE
Issues related to Veterans with ALS, access to ALS care, and appropriations funding.
Issues related to S.3822 - Break Up Big Medicine Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation Program in the One Big Beautiful Bill Act (P.L. 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to livestock and food pricing.
Issues related to workplace standards; Issues related to livestock and food pricing; Issues related to labor union work condition negotiation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Energy issues related to spent nuclear fuel policy, cybersecurity, and physical security; Issues related to permitting; Issues related to BLM.
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to permitting, affordability, and reliability.
Issues related to permitting, affordability, and reliability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Filing targets: Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to tariff policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Most Favored Nation policy; H.R. 3037 / S. 1500 Access to Breast Cancer Diagnostic Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Intellectual property and process patent related issues.
Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to affordability, transmission policy and workforce development; Issues related to transmission.
Issues related to affordability, transmission policy and workforce development; Issues related to transmission.
Filing targets: HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), SENATE
Issues related to Insulin pricing; Issues related to the pricing of GLP-1 therapeutic products; Issues regarding the 340B Drug Pricing Program; Issues related to H.R. 5316 - Drug Shortage Compounding Patient Access Act of 2025; Issues related to H.R. 6509 - SAFE Drugs Act of 2025; Issues related to S. 3794 - SAFE Drugs Act of 2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to energy efficiency and drinking water policy; Issues related to per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to the definition of water heater under energy conservation standards; Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to appliance standards & EPCA reform in H.R. 4626 - Don't Mess With My Home Appliances Act.
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs and other China issues.
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to appliance standards & EPCA reform in H.R. 4626 - Dont Mess With My Home Appliances Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Hurricane Helene Disaster Assistance.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2477 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation Program in the One Big Beautiful Bill Act (P.L. 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax pensions; Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to permitting, affordability, and reliability.
Issues related to permitting, affordability, and reliability.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to prescription drug pricing; Issues related to World Trade Organization IP waiver; Issues related to pharmaceutical intellectual property; Issues related to international trade; Issues related to the 340b program.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to the 340b program.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the report accompanying the FY 26 Senate Labor-HHS-Education Appropriations; Issues related to Rx drug pricing in the One Big Beautiful Bill Act (P.L. 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to proposed cuts in the CY 2025 Medicare Physician Fee Schedule proposed rule; Issues related to Medicare physician fee schedule.
Issues related to surprise billing; Issues related to prior authorization in Medicare and Medicaid.
Issues related to the Medicare Physician Fee Schedule and Authorized Use Criteria (AUC) in the One Big Beautiful Bill Act (PL 119-21).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to energy efficiency and drinking water policy; Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to section 301 tariffs and other China issues.
Issues related to energy efficiency and drinking water policy; Issues related to per- and polyfluoroalkyl substances (PFAS) legislation; Issues related to the definition of water heater under energy conservation standards; Issues related to clean energy tax credits; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to appliance standards & EPCA reform in H.R. 4626 - Don't Mess With My Home Appliances Act.
Issues related to polyfluoroalkyl substances (PFAS) legislation; Issues related to PL 119-6 - Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Department of Energy relating to "Energy Conservation Program: Energy Conservation Standards for Consumer Gas-fired Instantaneous Water Heaters".
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
Issues related to workplace standards; Issues related to livestock and food pricing.
Issues related to Xylazine usage.
Issues related to livestock and food pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE